Cytosorbents (CTSO) vs Fractyl Health (GUTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cytosorbents (CTSO) has outperformed Fractyl Health (GUTS) over the past year, losing 70.6% versus a loss of 95.1%. Cytosorbents is the larger company by market cap ($13.1 million vs $10.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTSO | GUTS |
|---|---|---|
| Share price | $4.16 | $0.82 |
| Market cap | $13.12M | $10.88M |
| 1-day change | -18.91% | -14.16% |
| YTD return | -67.45% | -96.89% |
| 1-year return | -70.58% | -95.12% |
| 5-year return | -95.62% | — |
| EPS (TTM) | $-5.62 | $-3.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $37.06M | $0 |
| Revenue growth (YoY) | +4.12% | -100.00% |
| Net income (latest FY) | $-8.20M | $-140.95M |
| Gross margin | 71.48% | — |
| Operating margin | -39.79% | — |
| Net margin | -22.12% | — |
| 52-week high | $17.00 | $29.34 |
| 52-week low | $2.84 | $0.784 |
| Distance from 52-week high | -75.53% | -97.21% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1041.83% | +7265.85% |
| Average volume | 37.34K | 504.39K |
| Shares outstanding | 3.15M | 13.26M |
| Employees | 129 | 100 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTSO has outperformed GUTS by 24.5 percentage points over the past year.
- Cytosorbents grew revenue faster in its latest fiscal year (+4.12% vs -100.00%).
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Health Care · Medical/Dental Instruments · 129 employees
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
CTSO vs GUTS FAQ
Which is bigger, Cytosorbents or Fractyl Health?
Cytosorbents (CTSO) is larger, with a market capitalization of $13.12M compared with $10.88M for Fractyl Health (GUTS).
Which stock has performed better over the past year, CTSO or GUTS?
CTSO returned -70.58% over the past 12 months, compared with -95.12% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Cytosorbents and Fractyl Health in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.